HSK40495 / Haisco - LARVOL DELTA

HSK40495, a highly selective PARP1 inhibitor with improved hematopoietic safety for the treatment of HRD cancers (AACR 2024) - "Importantly, in CD34+ human bone marrow progenitor cell, HSK40495 showed improved cytotoxicity when compare to first-generation PARP inhibitor, Talazoparib. In summary, HSK40495, a highly selective PARP1inhibitor over other PARP family members, exhibits excellent pharmacological and safety properties, and also has the favorable pharmacokinetics profile in preclinical studies. All these findings suggest that HSK40495 has the great potential to be a promising PARP1 inhibitor for further development in the patients with HRD tumors."

Clinical • Oncology • BRCA • CD34 • HRD • PARP2